ANDROGEN COMPOSITION FOR TREATING AN OPTHALMIC CONDITION

By Inventors: John T. Trogden, Adnan K. Salameh, Chetan P. Pujara, Anuradha V. Gore, and Jaya Giyanani

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application is based, and claims priority under 35 U.S.C. § 120 to U.S. Provisional Patent Application No. 61/436,274 filed on January 26, 2011, and which is incorporated herein by reference.

BACKGROUND

[0002] Blepharitis is a disorder of the meibomian glands, which produce the lipid component of tear film. Both the upper and lower eye lids contain 30-40 glands, located beneath the skin. The glandular pores open just behind the base of the eye lashes on the eye lid margin. With blepharitis, the glands become inflamed and the pores become blocked. Symptoms of blepharitis include eye irritation, soreness, redness and an accumulation of matter on the eyelids. Patients may also experience dry eye as well. As a result of these symptoms, blepharitis is commonly misdiagnosed as conjunctivitis or dry eye.

[0003] In certain cases, a local androgen deficiency can cause blepharitis. Topical compositions containing an androgen would be desirable for the treatment of blepharitis.

BRIEF SUMMARY

[0004] The disclosure provides compositions and methods for treating one or more ocular conditions.

[0004a] In one aspect, there is provided a ophtnalmic emulsion comprising an active ingredient, the active ingredient consisting of a physiologically effective amount of testosterone, and castor oil said emulsion is suitable for topical administration to an eye; and wherein the testosterone is present in the emulsion in an amount from about 0.01 w/w % to about 0.30 w/w%.

[0005] In one embodiment, a composition is provided comprising a physiologically effective amount of an androgen, wherein said composition is suitable for topical administration to an eye.

[0006] In another embodiment, a method for treating an ocular condition resulting from an androgen deficiency is disclosed. The method comprises administering an effective amount of an ophthalmic composition comprising a physiologically effective amount of an androgen, wherein said composition is suitable

6. The emulsion of claim 1_wherein the castor oil is present in the emulsion in an amount of 0.25 w/w %.